Rhythm Appoints Adam Zembrzuski as Chief Commercial Officer

Highlights

- ✓ **Rhythm has appointed Adam Zembrzuski as Chief Commercial Officer (CCO), effective 18 November 2026**
- ✓ **Adam brings 21 years' commercial leadership experience in clinical diagnostics, medical devices and health technology software-as-a-service (SaaS) at several organisations including Abbott Laboratories and most recently as General Manager at Labflow**
- ✓ **Adam will lead Rhythm's global commercial growth strategy, encompassing the prioritisation and launch of pipeline products and the continued commercial expansion, adoption and revenue growth of ColoSTAT® and geneType™**
- ✓ **Adam will report to the CEO and join Rhythm's Executive Leadership Team**

Melbourne, Australia, 17 November 2026: Rhythm Biosciences Ltd (ASX: RHY) ('**Rhythm**' or the '**Company**') has appointed Adam Zembrzuski as its Chief Commercial Officer, effective 18 November 2026. Mr Zembrzuski will lead the continued expansion of Rhythm's global commercial strategy, spanning its development pipeline and marketed products.

Rhythm has established commercial operations for its ColoSTAT® and geneType™ diagnostic platforms, supported by existing laboratory, distribution and clinical partnerships. Mr Zembrzuski's appointment strengthens the Company's commercial leadership as it focuses on accelerating revenue growth by increasing clinical adoption and expanding market penetration. As CCO, he will have executive accountability for the continued execution of Rhythm's commercial strategy, including product positioning, pricing, sales, marketing and the further development of its distribution and laboratory partnerships.

About Mr Zembrzuski

Mr Zembrzuski has 21 years of experience in the clinical diagnostics, medical devices and health technology SaaS sectors. Most recently, he served as General Manager at Labflow, where he drove strategic expansion across Australia and Asia-Pacific, delivering significant revenue growth by closing core enterprise and government partnerships and shaping the commercial positioning through to a successful acquisition. Prior to that, Adam held senior commercial roles, including Country Manager at Abbott Laboratories and LivaNova. Mr Zembrzuski holds an MBA and Bachelor of Applied Science qualifications, and is based in Melbourne, Australia.

As CCO, Mr Zembrzuski will be responsible for:

- **Commercial strategy:** refining and executing commercial growth priorities for ColoSTAT® and geneType™, including target customer segments and markets, and the prioritisation and launch of pipeline products.
- **Sales and partnerships:** driving revenue growth in target markets and managing Rhythm's distribution and laboratory partner relationships.
- **Reimbursement and market access:** leading pricing and reimbursement strategy, including engagement with the Medical Services Advisory Committee (MSAC).
- **Commercial organisation:** further building and leading Rhythm's commercial, marketing and market access functions as the Company scales its existing commercial operations.

"With both ColoSTAT® and geneType™ already commercially available, our focus is on accelerating adoption, expanding market access and growing revenue. Adam brings a strong record of launching and selling clinical diagnostic tests and the experience we need to broaden patient and clinician access to our portfolio. We are delighted to welcome him to Rhythm," said Dr David Atkins, CEO and Managing Director of Rhythm.

"Rhythm is at a pivotal inflection point, and the opportunity to scale world-class diagnostic technology that addresses critical health challenges is what drew me to the company. I am thrilled to join David and the team to accelerate our commercial pipeline and deliver meaningful outcomes for patients, clinicians and shareholders. My initial priority will be to engage with key clinical and industry stakeholders to unlock our immediate commercial pipeline," said Adam Zembrzuski, Chief Commercial Officer of Rhythm.

- ENDS -

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.

For further information contact us via investors@rhythmbio.com.

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an innovative Australian medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer, and saving lives. Rhythm Biosciences is committed to working with like-minded global partners to achieve commercialisation and distribution of these simple solutions. The Company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the Company on LinkedIn and X.

About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer can often be cured. The ColoSTAT® test is Rhythm Biosciences' simple blood-based test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood of CRC. It is intended for individuals with symptoms associated with CRC. The ColoSTAT® test is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

About geneType™

geneType™ is a sophisticated genetic risk assessment testing platform that combines clinical, family history and genetic data to provide comprehensive risk assessments for various diseases. The platform leverages polygenic risk scores and clinical risk factors to generate personalised health insights, helping individuals and healthcare providers make more informed medical decisions. The technology allows for risk assessment across multiple conditions including breast cancer, cardiovascular disease, diabetes, colorectal cancer, prostate cancer, and melanoma. The tests are delivered through healthcare providers and genetic counsellors, ensuring appropriate clinical oversight and support for patients receiving their results. The platform's multi-disease assessment capabilities and clinical utility position it well to capture growing demand in the preventative healthcare and precision medicine markets. For more information, please visit www.genetype.com.